Aurinia Pharmaceuticals Inc. (AUPH)
USD 7.36
(-5.83%)
USD 7.36
(-5.83%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -63.04 Million USD | 35.71% |
| 2022 | -103.64 Million USD | 37.6% |
| 2021 | -177.44 Million USD | -85.71% |
| 2020 | -102.91 Million USD | -18.77% |
| 2019 | -89.77 Million USD | -81.44% |
| 2018 | -53.92 Million USD | -105.87% |
| 2017 | -45.6 Million USD | -4.11% |
| 2016 | -21.33 Million USD | 22.71% |
| 2015 | -22.02 Million USD | -71.67% |
| 2014 | -15.69 Million USD | -388.25% |
| 2013 | -5.85 Million USD | 30.94% |
| 2012 | -8.93 Million USD | -222.01% |
| 2011 | -1.69 Million USD | 66.48% |
| 2010 | -4.26 Million USD | 44.3% |
| 2009 | -5.2 Million USD | 45.54% |
| 2008 | -14.21 Million USD | 58.5% |
| 2007 | -34.11 Million USD | -51.58% |
| 2006 | -22.6 Million USD | 19.72% |
| 2005 | -28.15 Million USD | -35.14% |
| 2004 | -20.83 Million USD | -111.94% |
| 2003 | -9.82 Million USD | -1040.31% |
| 2002 | -861.96 Thousand USD | 88.03% |
| 2001 | -7.19 Million USD | -13.74% |
| 2000 | -6.32 Million USD | -521.33% |
| 1999 | -1.08 Million USD | 57.71% |
| 1998 | -1.95 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -5.84 Million USD | 80.75% |
| 2024 Q2 | 4.11 Million USD | 213.45% |
| 2023 Q2 | -11.35 Million USD | 61.63% |
| 2023 Q4 | -15.65 Million USD | -141.27% |
| 2023 Q3 | -6.48 Million USD | 42.85% |
| 2023 Q1 | -29.58 Million USD | -5.28% |
| 2023 FY | - USD | 35.71% |
| 2022 Q3 | -8.69 Million USD | 75.28% |
| 2022 Q2 | -35.14 Million USD | 5.12% |
| 2022 Q1 | -37.04 Million USD | -15.1% |
| 2022 FY | - USD | 37.6% |
| 2022 Q4 | -28.1 Million USD | -223.36% |
| 2021 Q1 | -48.08 Million USD | -2401.77% |
| 2021 Q2 | -46.43 Million USD | 3.44% |
| 2021 FY | - USD | -85.71% |
| 2021 Q4 | -32.18 Million USD | 35.21% |
| 2021 Q3 | -49.67 Million USD | -6.97% |
| 2020 Q2 | -25.98 Million USD | -5.72% |
| 2020 Q3 | -35.96 Million USD | -38.44% |
| 2020 Q4 | -1.92 Million USD | 94.66% |
| 2020 Q1 | -24.57 Million USD | 12.21% |
| 2020 FY | - USD | -18.77% |
| 2019 Q3 | -22.98 Million USD | -43.64% |
| 2019 Q4 | -27.99 Million USD | -21.78% |
| 2019 Q2 | -16 Million USD | -16.88% |
| 2019 FY | - USD | -81.44% |
| 2019 Q1 | -13.69 Million USD | 0.17% |
| 2018 Q3 | -8.77 Million USD | 26.5% |
| 2018 Q1 | -9.97 Million USD | 51.99% |
| 2018 FY | - USD | -105.87% |
| 2018 Q4 | -13.71 Million USD | -56.3% |
| 2018 Q2 | -11.93 Million USD | -19.66% |
| 2017 Q3 | -13.69 Million USD | 18.99% |
| 2017 FY | - USD | -4.11% |
| 2017 Q4 | -20.78 Million USD | -51.7% |
| 2017 Q1 | 30.21 Million USD | 511.3% |
| 2017 Q2 | -16.91 Million USD | -155.97% |
| 2016 Q2 | -5.45 Million USD | -8.47% |
| 2016 Q4 | -7.34 Million USD | -145.49% |
| 2016 FY | - USD | 22.71% |
| 2016 Q3 | -2.99 Million USD | 45.18% |
| 2016 Q1 | -5.03 Million USD | 49.67% |
| 2015 Q3 | -5.92 Million USD | -4.44% |
| 2015 FY | - USD | -71.67% |
| 2015 Q2 | -5.67 Million USD | -9.96% |
| 2015 Q1 | -5.16 Million USD | -16.95% |
| 2015 Q4 | -9.99 Million USD | -68.66% |
| 2014 Q4 | -4.41 Million USD | -17.36% |
| 2014 Q3 | -3.76 Million USD | 9.96% |
| 2014 Q2 | -4.17 Million USD | -24.91% |
| 2014 Q1 | -3.34 Million USD | -323.63% |
| 2014 FY | - USD | -388.25% |
| 2013 Q3 | -938.36 Thousand USD | -13.75% |
| 2013 Q1 | -735.17 Thousand USD | 86.6% |
| 2013 Q4 | -789.37 Thousand USD | 15.88% |
| 2013 FY | - USD | 30.94% |
| 2013 Q2 | -824.96 Thousand USD | -12.21% |
| 2012 FY | - USD | -222.01% |
| 2012 Q4 | -5.48 Million USD | -272.53% |
| 2012 Q3 | -1.47 Million USD | 13.29% |
| 2012 Q2 | -1.69 Million USD | -142.45% |
| 2012 Q1 | 4 Million USD | 64.88% |
| 2011 Q1 | -1.55 Million USD | 31.14% |
| 2011 Q4 | 2.42 Million USD | 376.8% |
| 2011 Q3 | -876.93 Thousand USD | 46.99% |
| 2011 FY | - USD | 66.48% |
| 2011 Q2 | -1.65 Million USD | -6.69% |
| 2010 Q1 | -681.77 Thousand USD | 50.72% |
| 2010 FY | - USD | 44.3% |
| 2010 Q4 | -2.25 Million USD | -94.48% |
| 2010 Q3 | -1.15 Million USD | -449.77% |
| 2010 Q2 | -210.6 Thousand USD | 69.11% |
| 2009 Q1 | -2.25 Million USD | -150.62% |
| 2009 Q4 | -1.38 Million USD | 0.16% |
| 2009 FY | - USD | 45.54% |
| 2009 Q2 | -2.05 Million USD | 8.85% |
| 2009 Q3 | -1.38 Million USD | 32.48% |
| 2008 FY | - USD | 58.5% |
| 2008 Q4 | -898.39 Thousand USD | 74.02% |
| 2008 Q3 | -3.45 Million USD | 33.76% |
| 2008 Q2 | -5.21 Million USD | -7.79% |
| 2008 Q1 | -4.84 Million USD | 43.46% |
| 2007 Q1 | -6.7 Million USD | -15.38% |
| 2007 Q4 | -8.56 Million USD | -10.11% |
| 2007 Q3 | -7.77 Million USD | 17.25% |
| 2007 Q2 | -9.39 Million USD | -40.28% |
| 2007 FY | - USD | -51.58% |
| 2006 Q3 | -6.19 Million USD | -6.72% |
| 2006 Q2 | -5.8 Million USD | -28.59% |
| 2006 Q1 | -4.51 Million USD | 49.31% |
| 2006 Q4 | -5.8 Million USD | 6.32% |
| 2006 FY | - USD | 19.72% |
| 2005 Q3 | -4.98 Million USD | 24.14% |
| 2005 FY | - USD | -35.14% |
| 2005 Q2 | -6.56 Million USD | 5.35% |
| 2005 Q1 | -6.93 Million USD | 12.97% |
| 2005 Q4 | -8.91 Million USD | -78.92% |
| 2004 Q3 | -6.2 Million USD | -88.39% |
| 2004 FY | - USD | -111.94% |
| 2004 Q1 | -3.02 Million USD | 36.89% |
| 2004 Q4 | -7.97 Million USD | -28.47% |
| 2004 Q2 | -3.29 Million USD | -8.84% |
| 2003 Q3 | -3.82 Million USD | -284.42% |
| 2003 Q1 | -2.98 Million USD | -6.98% |
| 2003 FY | - USD | -1040.31% |
| 2003 Q4 | -4.79 Million USD | -25.48% |
| 2003 Q2 | 2.07 Million USD | 169.37% |
| 2002 Q1 | -2.26 Million USD | 0.0% |
| 2002 FY | - USD | 88.03% |
| 2002 Q4 | -2.79 Million USD | -250.76% |
| 2002 Q3 | 1.85 Million USD | -25.1% |
| 2002 Q2 | 2.47 Million USD | 208.96% |
| 2001 Q2 | -3.18 Million USD | -42.32% |
| 2001 Q1 | -2.23 Million USD | 10.72% |
| 2001 FY | - USD | -13.74% |
| 2001 Q3 | -2.31 Million USD | 35.09% |
| 2000 Q4 | -2.5 Million USD | -75.58% |
| 2000 Q2 | -1.66 Million USD | -120.1% |
| 2000 FY | - USD | -521.33% |
| 2000 Q1 | -758.06 Thousand USD | -56.83% |
| 2000 Q3 | -1.42 Million USD | 14.51% |
| 1999 Q4 | -483.36 Thousand USD | -463.68% |
| 1999 FY | - USD | 57.71% |
| 1999 Q1 | -132.58 Thousand USD | 0.0% |
| 1999 Q3 | -910.77 USD | 132.79% |
| 1999 Q2 | -405.39 Thousand USD | -205.77% |
| 1998 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AbCellera Biologics Inc. | -192.15 Million USD | 67.19% |
| Alkermes plc | 495.04 Million USD | 112.736% |
| Agenus Inc. | -145.92 Million USD | 56.795% |
| Aptorum Group Limited | -9.59 Million USD | -556.808% |
| Ardelyx, Inc. | -55.35 Million USD | -13.898% |
| Dyadic International, Inc. | -8.22 Million USD | -666.087% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | -21565.636% |
| Lantern Pharma Inc. | -15.78 Million USD | -299.368% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | -216.622% |
| Novavax, Inc. | -487.39 Million USD | 87.064% |
| Janux Therapeutics, Inc. | -71.02 Million USD | 11.231% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 19.678% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | -250.779% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | -532.494% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | -9.884% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 83.407% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | -161.477% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | 12018.147% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 59.892% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 15.729% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -212.749% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | -165.629% |
| Clearside Biomedical, Inc. | -23.05 Million USD | -173.428% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 48.366% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 75.586% |
| AlloVir, Inc. | -190.14 Million USD | 66.843% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 64.111% |
| VYNE Therapeutics Inc. | -29.25 Million USD | -115.486% |
| Bicycle Therapeutics plc | -183.4 Million USD | 65.623% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 61.887% |
| ChromaDex Corporation | -3.89 Million USD | -1519.081% |
| Chimerix, Inc. | -92.97 Million USD | 32.189% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -41.88% |
| Caribou Biosciences, Inc. | -112.53 Million USD | 43.975% |
| CRISPR Therapeutics AG | -202.7 Million USD | 68.897% |
| Precision BioSciences, Inc. | -32.04 Million USD | -96.764% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 63.394% |
| Fortress Biotech, Inc. | -133.64 Million USD | 52.824% |
| Fortress Biotech, Inc. | -133.64 Million USD | 52.824% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 18.484% |
| ImmuCell Corporation | -2.5 Million USD | -2417.774% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 51.659% |
| Immix Biopharma, Inc. | -16.13 Million USD | -290.731% |
| Incyte Corporation | 919.42 Million USD | 106.857% |
| Innoviva, Inc. | 248.96 Million USD | 125.324% |
| IO Biotech, Inc. | -91.22 Million USD | 30.891% |
| Jaguar Health, Inc. | -33.13 Million USD | -90.296% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 58.57% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | 161.977% |
| ContextLogic Inc. | -324 Million USD | 80.541% |
| MiMedx Group, Inc. | 40.51 Million USD | 255.606% |
| MEI Pharma, Inc. | 26.38 Million USD | 338.995% |
| NextCure, Inc. | -59.03 Million USD | -6.789% |
| Onconetix, Inc. | -36.7 Million USD | -71.759% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | 2920.895% |
| Opthea Limited | -200.01 Million USD | 68.479% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -2191.302% |
| Vaxcyte, Inc. | -464.88 Million USD | 86.438% |
| PDS Biotechnology Corporation | -40.08 Million USD | -57.283% |
| Precigen, Inc. | -89.22 Million USD | 29.34% |
| Pharming Group N.V. | 9.87 Million USD | 738.321% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 60.36% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | -176.984% |
| PureTech Health plc | -11.62 Million USD | -442.246% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | -271.28% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 72.999% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | -161.477% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 27.886% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | -117.681% |
| Acelyrin, Inc. | -381.52 Million USD | 83.475% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | -489209.571% |
| Summit Therapeutics Inc. | 1 Million USD | 6398.402% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | -88.843% |
| Senti Biosciences, Inc. | -61.33 Million USD | -2.79% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 43.86% |
| Elevation Oncology, Inc. | -41.46 Million USD | -52.041% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | -104.009% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | -930.761% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | -19540.81% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | -94.272% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | -650.917% |
| Wave Life Sciences Ltd. | -58.79 Million USD | -7.241% |
| Seer, Inc. | -97.88 Million USD | 35.591% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | -1.367% |
| Aadi Bioscience, Inc. | -65.36 Million USD | 3.546% |
| ESSA Pharma Inc. | -26.45 Million USD | -138.315% |
| GlycoMimetics, Inc. | -39.12 Million USD | -61.155% |
| GT Biopharma, Inc. | 5.97 Million USD | 1154.474% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 69.497% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | -817.982% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 172.625% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | -11.088% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | -23.093% |
| Alzamend Neuro, Inc. | -9.88 Million USD | -537.682% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 88.323% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -815.848% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | -34.538% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 73.355% |
| Aptose Biosciences Inc. | -52.26 Million USD | -20.623% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 41.484% |
| Soligenix, Inc. | -7.85 Million USD | -702.855% |
| Century Therapeutics, Inc. | -121.2 Million USD | 47.984% |
| Kura Oncology, Inc. | -164.95 Million USD | 61.779% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 21.288% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | -525.094% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | -6482.9% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | -1363.147% |
| Autolus Therapeutics plc | -156.77 Million USD | 59.784% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 25.527% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | 8.629% |
| Eterna Therapeutics Inc. | -19.93 Million USD | -216.279% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 66.69% |
| GRI Bio, Inc. | -10.89 Million USD | -478.519% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -1296.169% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 48.536% |
| IGM Biosciences, Inc. | -253.35 Million USD | 75.115% |
| INmune Bio, Inc. | - USD | Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 39.256% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | -65.334% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -311.241% |
| Entero Therapeutics, Inc. | -15.74 Million USD | -300.47% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | -10.91% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 41.134% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 76.298% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 67.491% |
| Verastem, Inc. | -83.16 Million USD | 24.191% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -24.668% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 60.154% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 44.739% |
| Histogen Inc. | -10.5 Million USD | -500.276% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | -341.515% |
| Surrozen, Inc. | -41.13 Million USD | -53.283% |
| Organovo Holdings, Inc. | -14.8 Million USD | -325.821% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 1966018.304% |
| Ovid Therapeutics Inc. | -58.71 Million USD | -7.381% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | -22.913% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | -192.711% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | -656.14% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 62.035% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | -27.992% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | -160.891% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | -318.777% |
| Apollomics, Inc. | -171.74 Million USD | 63.291% |
| Amarin Corporation plc | -50.9 Million USD | -23.861% |
| Mesoblast Limited | -61.33 Million USD | -2.798% |
| Turnstone Biologics Corp. | -56.23 Million USD | -12.115% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 55.973% |
| Synaptogenix, Inc. | -8.3 Million USD | -658.916% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | -311.024% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -1215.819% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | 14794.934% |
| Exelixis, Inc. | 196.6 Million USD | 132.068% |
| Better Therapeutics, Inc. | -38.26 Million USD | -64.777% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 55.415% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 87.269% |
| NLS Pharmaceutics AG | -11.79 Million USD | -434.493% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | 25602.799% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | -113.675% |
| Gritstone bio, Inc. | -126.86 Million USD | 50.303% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 2.982% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -1476.196% |
| Avid Bioservices, Inc. | -11.48 Million USD | -449.142% |
| Insmed Incorporated | -654.73 Million USD | 90.371% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | -2702.439% |
| MediWound Ltd. | -4.89 Million USD | -1188.514% |
| OmniAb, Inc. | -49.73 Million USD | -26.776% |
| Alector, Inc. | -142.89 Million USD | 55.878% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 26.204% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | -20.9% |
| Zai Lab Limited | -366.57 Million USD | 82.801% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 78.307% |
| Aura Biosciences, Inc. | -83.69 Million USD | 24.671% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 72.01% |
| Immunic, Inc. | -99.11 Million USD | 36.388% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 52.117% |
| Veracyte, Inc. | -49.4 Million USD | -27.602% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | -792.52% |
| FibroGen, Inc. | -261.4 Million USD | 75.881% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -465.901% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -800.501% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | -236.846% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 104.35% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | -148.002% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | 258.052% |
| TG Therapeutics, Inc. | 26.1 Million USD | 341.559% |
| Galecto, Inc. | -37.51 Million USD | -68.04% |
| Calithera Biosciences, Inc. | -38.26 Million USD | -64.764% |
| Fortrea Holdings Inc. | 167.3 Million USD | 137.685% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 53.048% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | -122.694% |
| XBiotech Inc. | -35.76 Million USD | -76.276% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 2.982% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | 3.376% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 39.642% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | -145.587% |
| Theravance Biopharma, Inc. | -40.86 Million USD | -54.274% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 87.792% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | -12.542% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -112381.49% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 45.806% |
| Gain Therapeutics, Inc. | -22.16 Million USD | -184.386% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 73.179% |
| NexImmune, Inc. | -28.16 Million USD | -123.829% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | -1041.009% |
| Marker Therapeutics, Inc. | -11.79 Million USD | -434.647% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 101.355% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | -148.295% |
| Scopus BioPharma Inc. | -11.71 Million USD | -438.258% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 49.901% |
| Ainos, Inc. | -8.77 Million USD | -618.64% |
| Pluri Inc. | -20.22 Million USD | -211.728% |
| Prothena Corporation plc | -190.1 Million USD | 66.836% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 50.821% |
| Celularity Inc. | -183.94 Million USD | 65.725% |
| Rallybio Corporation | -72.37 Million USD | 12.886% |
| Cue Biopharma, Inc. | -46.05 Million USD | -36.904% |
| MeiraGTx Holdings plc | -57.05 Million USD | -10.508% |
| Omeros Corporation | -163.61 Million USD | 61.465% |
| Humacyte, Inc. | -96.45 Million USD | 34.638% |
| Immunocore Holdings plc | -59.64 Million USD | -5.697% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | -225.454% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | -158.761% |
| Blueprint Medicines Corporation | -474.61 Million USD | 86.716% |
| CalciMedica, Inc. | -34.18 Million USD | -84.407% |
| Cabaletta Bio, Inc. | -73.23 Million USD | 13.91% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 49.762% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 62.572% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 75.02% |
| Pulmatrix, Inc. | -12.64 Million USD | -398.553% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | -91.249% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 28.734% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 87.548% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 37.71% |
| Cytokinetics, Incorporated | -456.68 Million USD | 86.195% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | -88.916% |
| Nutriband Inc. | -5.12 Million USD | -1130.959% |
| Protara Therapeutics, Inc. | -43.27 Million USD | -45.699% |
| Vor Biopharma Inc. | -114.37 Million USD | 44.875% |
| Roivant Sciences Ltd. | -996.51 Million USD | 93.673% |
| Evogene Ltd. | -23.2 Million USD | -171.707% |
| ProKidney Corp. | -147.66 Million USD | 57.305% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 2.306% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | -41067.099% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 88.85% |
| CorMedix Inc. | -48.88 Million USD | -28.965% |
| BioLineRx Ltd. | -57.06 Million USD | -10.491% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 43.586% |
| Galectin Therapeutics Inc. | -202 Thousand USD | -31111.386% |
| Atai Life Sciences N.V. | -36.31 Million USD | -73.631% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 20.713% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 22.464% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 77.116% |
| Sagimet Biosciences Inc. | -30.74 Million USD | -105.098% |
| MediciNova, Inc. | -9.87 Million USD | -538.129% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 49.939% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -4020.178% |
| GeoVax Labs, Inc. | -26.66 Million USD | -136.408% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 71.978% |
| Biomea Fusion, Inc. | -124.62 Million USD | 49.409% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 80.915% |
| Mereo BioPharma Group plc | -26.05 Million USD | -141.967% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 66.876% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 72.581% |
| Absci Corporation | -95.45 Million USD | 33.952% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | -109.982% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 41.142% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 72.996% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | -175.856% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 69.665% |
| Allakos Inc. | -189.91 Million USD | 66.803% |
| Imunon, Inc. | -19.87 Million USD | -217.165% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 41.888% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 158.202% |
| BioAtla, Inc. | -122.24 Million USD | 48.424% |
| NLS Pharmaceutics AG | -11.79 Million USD | -434.493% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | -300.019% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 79.005% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | -52.115% |
| XOMA Corporation | -39.36 Million USD | -60.172% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 36.479% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 46.411% |
| aTyr Pharma, Inc. | -52.17 Million USD | -20.831% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 24.778% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 57.582% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 73.122% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | -361.781% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | -683.942% |
| Akari Therapeutics, Plc | -16.8 Million USD | -275.235% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 33510.172% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 113.95% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -886.863% |
| UroGen Pharma Ltd. | -63.83 Million USD | 1.228% |
| Sutro Biopharma, Inc. | -67.91 Million USD | 7.168% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -768.056% |
| Orgenesis Inc. | -60.71 Million USD | -3.836% |
| Entera Bio Ltd. | -8.8 Million USD | -616.118% |
| GH Research PLC | -41.15 Million USD | -53.201% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | -147.059% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 23.331% |
| Xencor, Inc. | -125.87 Million USD | 49.913% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | -4319.559% |
| Replimune Group, Inc. | -230.19 Million USD | 72.612% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | -212.77% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | -476.193% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -886.863% |
| Portage Biotech Inc. | -18.19 Million USD | -246.431% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -4020.178% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 39.716% |
| OncoCyte Corporation | -23.12 Million USD | -172.659% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -457.92% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -450.3% |
| Purple Biotech Ltd. | -22.22 Million USD | -183.676% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | -883.573% |
| scPharmaceuticals Inc. | -46.06 Million USD | -36.877% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | -254.004% |
| HilleVax, Inc. | -132.46 Million USD | 52.405% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | -492.937% |
| Tharimmune, Inc. | -9.3 Million USD | -577.736% |
| Genprex, Inc. | -31.06 Million USD | -102.981% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 66.38% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | -101.081% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | -8152.225% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | 41879.542% |
| OKYO Pharma Limited | -15.74 Thousand USD | -400303.407% |
| Savara Inc. | -59.13 Million USD | -6.619% |
| Curis, Inc. | -45.13 Million USD | -39.673% |
| Daré Bioscience, Inc. | -30.7 Million USD | -105.355% |
| Carmell Therapeutics Corporation | -15.19 Million USD | -315.025% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | -779.93% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | -135.831% |
| BeiGene, Ltd. | -1.12 Billion USD | 94.394% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | -286.763% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 85.358% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 30.211% |
| Erasca, Inc. | -121.31 Million USD | 48.028% |
| bluebird bio, Inc. | -167.16 Million USD | 62.284% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -1301.432% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 120.319% |
| DBV Technologies S.A. | -85.98 Million USD | 26.674% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -1301.432% |
| Moderna, Inc. | -3.28 Billion USD | 98.08% |
| Vincerx Pharma, Inc. | -42.6 Million USD | -47.966% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | -1016.271% |
| Molecular Templates, Inc. | 1.43 Million USD | 4508.881% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | -5.338% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 80.675% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 54.01% |
| Spruce Biosciences, Inc. | -47.36 Million USD | -33.106% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 54.654% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 69.374% |
| MacroGenics, Inc. | 2.01 Million USD | 3225.781% |
| RenovoRx, Inc. | -11.39 Million USD | -453.529% |
| Adicet Bio, Inc. | -136.53 Million USD | 53.824% |
| Prime Medicine, Inc. | -193.75 Million USD | 67.461% |
| Aditxt, Inc. | -25.45 Million USD | -147.651% |
| Adagene Inc. | -14.95 Million USD | -321.697% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -762.464% |
| Quantum-Si incorporated | -91.8 Million USD | 31.324% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 108.85% |
| Acurx Pharmaceuticals, Inc. | - USD | Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | 149.857% |
| SciSparc Ltd. | -5.28 Million USD | -1093.62% |
| Vericel Corporation | 2.86 Million USD | 2301.362% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -66120.276% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | -190.654% |
| Generation Bio Co. | -133.3 Million USD | 52.703% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 24.067% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 26.709% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 72.279% |
| Invivyd, Inc. | -196.61 Million USD | 67.934% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 83.149% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | -579.767% |
| Spero Therapeutics, Inc. | 27.15 Million USD | 332.183% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -513.0% |
| 2seventy bio, Inc. | -206.41 Million USD | 69.457% |
| ADMA Biologics, Inc. | 5.12 Million USD | 1331.387% |
| Clene Inc. | -43.24 Million USD | -45.804% |
| Capricor Therapeutics, Inc. | -23 Million USD | -174.01% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | -30.055% |
| GeoVax Labs, Inc. | -26.66 Million USD | -136.408% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 78.954% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | -71.653% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | 367.454% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | 1383.986% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | -94.098% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 60.199% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 90.787% |
| Evaxion Biotech A/S | -21.4 Million USD | -194.571% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | 5.071% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 71.035% |
| Trevena, Inc. | -35.28 Million USD | -78.664% |
| Surrozen, Inc. | -41.13 Million USD | -53.283% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 20.787% |
| Cingulate Inc. | -22.95 Million USD | -174.69% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | -745.021% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -69.104% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | -666.401% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 38.35% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | 7.047% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | -8.009% |
| Clearmind Medicine Inc. | -8.71 Million USD | -623.791% |
| Kronos Bio, Inc. | -121.83 Million USD | 48.25% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | 15.193% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -2482.397% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 37.47% |
| Statera Biopharma, Inc. | 38.93 Million USD | 261.929% |
| ImmunityBio, Inc. | -436.18 Million USD | 85.546% |
| Korro Bio, Inc. | -80.9 Million USD | 22.072% |
| Kineta, Inc. | -15.71 Million USD | -301.215% |
| BioVie Inc. | -31.95 Million USD | -97.329% |
| Codexis, Inc. | -49.28 Million USD | -27.928% |
| Celularity Inc. | -183.94 Million USD | 65.725% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 71.538% |
| Celcuity Inc. | -58.3 Million USD | -8.124% |
| Virax Biolabs Group Limited | -6.6 Million USD | -853.936% |
| Cibus, Inc. | -314.58 Million USD | 79.959% |
| Eledon Pharmaceuticals, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | -86.9% |
| IN8bio, Inc. | -28.5 Million USD | -121.187% |
| Kodiak Sciences Inc. | -259.02 Million USD | 75.66% |
| Annexon, Inc. | -141.57 Million USD | 55.467% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 44.007% |
| Assembly Biosciences, Inc. | -64.19 Million USD | 1.79% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | -125.53% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 72.589% |
| Eyenovia, Inc. | -24.1 Million USD | -161.54% |
| Puma Biotechnology, Inc. | 44.78 Million USD | 240.78% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -19358.951% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | 14.575% |
| Arcellx, Inc. | -64.14 Million USD | 1.712% |
| Cardiff Oncology, Inc. | -45.01 Million USD | -40.061% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 48.94% |
| Regulus Therapeutics Inc. | -30.88 Million USD | -104.155% |
| Moolec Science SA | -52.07 Million USD | -21.068% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | -22.17% |
| Geron Corporation | -174.78 Million USD | 63.928% |
| LAVA Therapeutics N.V. | -40.41 Million USD | -55.991% |
| Royalty Pharma plc | 1.88 Billion USD | 103.341% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 47.282% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -576.161% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | -203.976% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 62.038% |
| Humacyte, Inc. | -96.45 Million USD | 34.638% |
| Structure Therapeutics Inc. | -102.45 Million USD | 38.466% |
| 89bio, Inc. | -134.46 Million USD | 53.112% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 20.067% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | 1655.948% |
| Genelux Corporation | -24.16 Million USD | -160.902% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | -86.53% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 61.431% |
| Notable Labs, Ltd. | -14.4 Million USD | -337.826% |
| Liquidia Corporation | -70.05 Million USD | 9.998% |
| Mustang Bio, Inc. | -48.06 Million USD | -31.176% |
| Immunovant, Inc. | -269.97 Million USD | 76.647% |
| Quantum-Si incorporated | -91.8 Million USD | 31.324% |
| Arbutus Biopharma Corporation | -70.98 Million USD | 11.184% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | -226.533% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 38.196% |
| Acasti Pharma Inc. | -11.3 Million USD | -457.889% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | -183.316% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -311.241% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 70.051% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | -1376.392% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | -297.021% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | -119.096% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | -70.259% |
| PepGen Inc. | -83.58 Million USD | 24.569% |
| Moleculin Biotech, Inc. | -29.5 Million USD | -113.69% |
| United Therapeutics Corporation | 1.38 Billion USD | 104.546% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | -175.35% |
| Solid Biosciences Inc. | -93.43 Million USD | 32.522% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | -1221.259% |
| Immuneering Corporation | -58.06 Million USD | -8.588% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 1966018.304% |
| Silo Pharma, Inc. | -3.62 Million USD | -1638.645% |
| Belite Bio, Inc | -31.52 Million USD | -99.965% |
| XOMA Corporation | -39.36 Million USD | -60.172% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | 6.524% |
| Bionomics Limited | -9.83 Million USD | -540.917% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 24.931% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | -82.185% |
| uniQure N.V. | -253.1 Million USD | 75.09% |
| Cassava Sciences, Inc. | -95.68 Million USD | 34.111% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -762.464% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 51.317% |
| Forte Biosciences, Inc. | -32.47 Million USD | -94.128% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | -683.147% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | -123.42% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -19358.951% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -465.901% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | -296.497% |
| Altimmune, Inc. | -87.93 Million USD | 28.303% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 31.529% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | -82.185% |
| Compugen Ltd. | -12.51 Million USD | -403.731% |
| Peak Bio, Inc. | -1356.23 USD | -4648595.28% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | -29.732% |
| Benitec Biopharma Inc. | -22.49 Million USD | -180.333% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 73.98% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | -120.884% |
| Zura Bio Limited | -60.56 Million USD | -4.102% |
| PolyPid Ltd. | -20.26 Million USD | -211.143% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | -303.811% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | -120.884% |
| Instil Bio, Inc. | -146.12 Million USD | 56.853% |
| argenx SE | -216.02 Million USD | 70.815% |
| Immunome, Inc. | -28.27 Million USD | -123.009% |
| Compass Therapeutics, Inc. | -48.47 Million USD | -30.066% |
| Verona Pharma plc | -52.46 Million USD | -20.164% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 33.475% |
| Shattuck Labs, Inc. | -87.61 Million USD | 28.041% |
| CervoMed Inc. | -2.17 Million USD | -2802.885% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 48.425% |
| Plus Therapeutics, Inc. | -12.69 Million USD | -396.707% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | -30.874% |
| Moolec Science SA | -52.07 Million USD | -21.068% |
| Enveric Biosciences, Inc. | -17.13 Million USD | -267.836% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 51.648% |
| AnaptysBio, Inc. | -143.16 Million USD | 55.962% |
| Design Therapeutics, Inc. | -66.32 Million USD | 4.942% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 22.152% |
| NeurAxis, Inc. | -6.66 Million USD | -846.013% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | -67.012% |
| Lumos Pharma, Inc. | -36.57 Million USD | -72.401% |
| Achilles Therapeutics plc | -70.44 Million USD | 10.498% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 33.475% |
| 180 Life Sciences Corp. | -22.13 Million USD | -184.842% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | 1181.563% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -2482.397% |
| Nutriband Inc. | -5.12 Million USD | -1130.959% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 42.553% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | -13.738% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | -24.722% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | 3.416% |
| MoonLake Immunotherapeutics | -54.1 Million USD | -16.516% |
| Palisade Bio, Inc. | -12.28 Million USD | -413.37% |
| Tourmaline Bio, Inc. | -45.37 Million USD | -38.943% |
| Beam Therapeutics Inc. | -156.47 Million USD | 59.707% |
| Neurogene Inc. | -52.28 Million USD | -20.581% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 53.808% |
| AEON Biopharma, Inc. | -48.36 Million USD | -30.367% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 32.221% |
| Sesen Bio, Inc. | -50.84 Million USD | -24.011% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 23.05% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | -410.501% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 85.25% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 40.068% |
| Athira Pharma, Inc. | -116.7 Million USD | 45.977% |
| Vaccinex, Inc. | -19.74 Million USD | -219.258% |
| HCW Biologics Inc. | -23.57 Million USD | -167.42% |
| XOMA Corporation | -39.36 Million USD | -60.172% |
| Nektar Therapeutics | -243.1 Million USD | 74.066% |
| Arvinas, Inc. | -394.8 Million USD | 84.031% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 33510.172% |
| Merus N.V. | -149.2 Million USD | 57.745% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 32.563% |
| Quince Therapeutics, Inc. | -31.26 Million USD | -101.686% |
| Rezolute, Inc. | -68.42 Million USD | 7.857% |
| Clene Inc. | -43.24 Million USD | -45.804% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | -308.807% |
| BeyondSpring Inc. | -21.54 Million USD | -192.697% |
| Synlogic, Inc. | -55.16 Million USD | -14.296% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | -421.783% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | -492.436% |
| Peak Bio, Inc. | -1356.23 USD | -4648595.28% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | -94.2% |
| Krystal Biotech, Inc. | 17.9 Million USD | 452.139% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 46.761% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 81.53% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | -1268.673% |
| MannKind Corporation | 15.12 Million USD | 516.729% |
| Ikena Oncology, Inc. | -74.39 Million USD | 15.256% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | -400.651% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | 410.164% |
| Gossamer Bio, Inc. | -172.15 Million USD | 63.377% |
| CohBar, Inc. | -12.06 Million USD | -422.528% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | -147.156% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | -109.982% |
| Legend Biotech Corporation | -477.87 Million USD | 86.807% |
| Mural Oncology plc | -192.72 Million USD | 67.286% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 44.722% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -290.498% |
| Disc Medicine, Inc. | -91.02 Million USD | 30.737% |
| Champions Oncology, Inc. | -5.05 Million USD | -1147.467% |
| REGENXBIO Inc. | -239.46 Million USD | 73.672% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -488.224% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -13.077% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | -62.625% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 44.11% |
| Vaxart, Inc. | -74.72 Million USD | 15.626% |
| PharmaCyte Biotech, Inc. | - USD | Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | -79.069% |
| Cellectis S.A. | -98.09 Million USD | 35.729% |
| Longeveron Inc. | -20.06 Million USD | -214.292% |
| Repare Therapeutics Inc. | -114.27 Million USD | 44.828% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 85.645% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 15.726% |
| Revolution Medicines, Inc. | -430.58 Million USD | 85.358% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | -902.496% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | -104.771% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 15.475% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | 1385.886% |
| Anixa Biosciences, Inc. | -10.96 Million USD | -474.984% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 101.369% |
| Denali Therapeutics Inc. | -179.97 Million USD | 64.969% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -66120.276% |
| Veru Inc. | -89.97 Million USD | 29.929% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | -134.567% |
| Cingulate Inc. | -22.95 Million USD | -174.69% |
| Passage Bio, Inc. | -98.34 Million USD | 35.889% |
| Context Therapeutics Inc. | -25.06 Million USD | -151.578% |
| Exicure, Inc. | -15.53 Million USD | -305.734% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 69.404% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | -70.508% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | -957.375% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 62.575% |
| Nuvalent, Inc. | -149.49 Million USD | 57.826% |
| ABVC BioPharma, Inc. | -8.13 Million USD | -675.256% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 26.599% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | -108.917% |
| OmniAb, Inc. | -49.73 Million USD | -26.776% |
| Anew Medical, Inc. | -1.3 Million USD | -4746.638% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | -409.924% |
| Lipocine Inc. | -16.32 Million USD | -286.254% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | 5.434% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | 15.149% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | -65.334% |
| G1 Therapeutics, Inc. | -39.01 Million USD | -61.601% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | -184.213% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 88.433% |
| Ocugen, Inc. | -64.82 Million USD | 2.746% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 31.893% |
| Q32 Bio Inc. | -86.5 Million USD | 27.115% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | -272.464% |
| Alumis Inc. Common Stock | -156.89 Million USD | 59.815% |
| Equillium, Inc. | -12.13 Million USD | -419.418% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | -7.824% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -697.725% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | -234.272% |
| Galera Therapeutics, Inc. | -46.69 Million USD | -35.027% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 40.715% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | -252.482% |
| Dominari Holdings Inc. | -22.44 Million USD | -180.958% |
| Edesa Biotech, Inc. | -8.19 Million USD | -669.791% |
| vTv Therapeutics Inc. | -25.41 Million USD | -148.099% |
| Bio-Techne Corporation | 326.66 Million USD | 119.3% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 83.618% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | 129.136% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 51.912% |
| Candel Therapeutics, Inc. | -37.43 Million USD | -68.435% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 58.275% |
| Nkarta, Inc. | -120.48 Million USD | 47.671% |
| BioCardia, Inc. | -11.56 Million USD | -445.389% |
| Iterum Therapeutics plc | -34.58 Million USD | -82.322% |